NOVATIM
An innovative biotechnology company committed to developing novel tumor immune-therapeutics through its own pioneer technology platform and affording drugs for unmet clinical needs
An innovative biotechnology company committed to developing novel tumor immune-therapeutics through its own pioneer technology platform and affording drugs for unmet clinical needs
An innovative biotechnology company committed to developing novel tumor immune-therapeutics through its own pioneer technology platform and affording drugs for unmet clinical needs
Novatim Immune Therapeutics (Zhejiang) Co., Ltd. was established in 2018 as an innovative biotechnology company committed to developing novel tumor immuno-therapeutics through its proprietary pioneer technology platform and affordable drugs for unmet clinical needs. It fully owns the subsidiary company of Shanghai Tinova Immune Therapeutics Co., Ltd..
MORE
Dr. Wu Guoxiang
Founder, Chairman and General Manager
Established in
FIC/BIC Products
Completed The First Round of Financing in
We are implementing an innovative product pipeline with unique features in the market, veering into more innovative or best-in-class candidate products in the field of tumor immunotherapies.
MORE
We focus on tumor immunotherapies, bring new hope to patients worldwide
